SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti–PD-1–Resistant Model of Non–Small Cell Lung Cancer
| Autor: | Yun Hu, Maria Angelica Cortez, Sara Mosaffa, Mark Wasley, Hari Menon, Ahmed I. Younes, Tugce Ozgen, Hampartsoum B. Barsoumian, Fatemeh Masropour, L. Yang, Vivek Verma, James W. Welsh, Dawei Chen, Katherine Klein |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Cancer Research Lung Neoplasms Mice 129 Strain medicine.medical_treatment Immunology Article B7-H1 Antigen Mice 03 medical and health sciences Antineoplastic Agents Immunological 0302 clinical medicine Immune system Piperidines Carcinoma Non-Small-Cell Lung Cell Line Tumor PD-L1 medicine Animals Neoplasm Lung cancer biology business.industry Protein Tyrosine Phosphatase Non-Receptor Type 6 Chemoradiotherapy Immunotherapy medicine.disease Mice Inbred C57BL Radiation therapy Pyrimidines 030104 developmental biology Drug Resistance Neoplasm 030220 oncology & carcinogenesis Cancer research biology.protein Adenocarcinoma Female business |
| Zdroj: | Cancer Immunol Res |
| ISSN: | 2326-6074 2326-6066 |
| DOI: | 10.1158/2326-6066.cir-19-0744 |
| Popis: | Immune checkpoint inhibitors, such as anti–PD-1/PD-L1, have emerged as promising therapies for advanced non–small cell lung cancer (NSCLC). However, approximately 80% of patients do not respond to immunotherapy given alone because of intrinsic or acquired resistance. Radiotherapy (XRT) can overcome PD-1 resistance and improve treatment outcomes, but its efficacy remains suboptimal. The tyrosine phosphatase SHP-2, expressed in some cancers and in immune cells, has been shown to negatively affect antitumor immunity. Our hypothesis was that SHP-2 inhibition in combination with anti–PD-L1 would enhance immune-mediated responses to XRT and synergistically boost antitumor effects in an anti–PD-1–resistant mouse model. We treated 129Sv/Ev mice with anti–PD-1–resistant 344SQ NSCLC adenocarcinoma with oral SHP099 (a SHP-2 inhibitor) combined with XRT and intraperitoneal anti–PD-L1. Primary tumors were treated with XRT (three fractions of 12 Gy each), whereas abscopal (out-of-field) tumors were observed but not treated. XRT in combination with SHP099 and anti–PD-L1 promoted local and abscopal responses, reduced lung metastases, and improved mouse survival. XRT also increased SHP-2+ M1 tumor-associated macrophages in abscopal tumors (P = 0.019). The addition of SHP099 also associated with a higher M1/M2 ratio, greater numbers of CD8+ T cells, and fewer regulatory T cells. This triple-combination therapy had strong antitumor effects in a mouse model of anti–PD-1–resistant NSCLC and may be a novel therapeutic approach for anti–PD-1–resistant NSCLC in patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|